Date: 2017-09-12
Type of information: Distribution agreement
Compound: Zevtera®/Mabelio® (ceftobiprole)
Company: Basilea Pharmaceutica (Switzerland) Cardiome Pharma (Canada)
Therapeutic area: Infectious diseases
Type agreement: distribution - commercialisation
Action mechanism:
- antibiotic/cephalosporin. Ceftobiprole belongs to the class of antibacterial agents known as cephalosporins. Its broad spectrum activity encompasses Gram-positive and Gram-negative bacteria, including anti-pseudomonal activity similar to cefepime. The rights for ceftobiprole have been transferred back to Basilea from Cilag GmbH International, a Johnson & Johnson company, in February 2011.
Disease: severe community-acquired and hospital-acquired pneumonia
Details:
- • On September 12, 2017, Basilea Pharmaceutica International has entered into a distribution agreement with Cardiome Pharma for Zevtera®/Mabelio® (ceftobiprole) in Europe (excluding Nordic countries) and Israel. Under the terms of the agreement, Cardiome is granted an exclusive license to commercialize ceftobiprole in more than 30 countries in Europe and in Israel.
- Ceftobiprole is currently approved in 13 European countries and commercialized in Italy, France, Germany, the U.K., Austria and Switzerland under the brand name Zevtera or Mabelio. Cardiome will assume responsibility for regulatory activities and commercialization in the territory. Basilea will supply Cardiome with the product at a transfer price.
- Basilea remains responsible for the commercialization of ceftobiprole in the territory during the transition of the commercial activities to Cardiome, which is expected to be completed by the end of 2017.
Financial terms:
- Basilea will receive an upfront payment of CHF 5 million and is eligible for additional payments upon achievement of pre-specified regulatory and commercial milestones.
Latest news:
Is general: Yes
